There are 412 resources available
1230P - hPG80 (circulating progastrin) is a new blood-based biomarker for diagnosis of early-stage non-small cell lung cancers
Presenter: Paul Hofman
Session: Poster session 14
2324P - Trametinib and PD-1 combined blockade impairs tumor growth and improves survival of KRAS-mutant lung cancer through Id1 downregulation
Presenter: Ander Puyalto
Session: Poster session 16
1432P - Tumor stage shift in lung cancer during the COVID-19 pandemic: A real-world data study of the Network Oncology Registry
Presenter: Anja Thronicke
Session: Poster session 20
1316MO - BL-B01D1, a first-in-class EGFRxHER3 bispecific antibody-drug conjugate, in patients with non-small cell lung cancer: Updated results from first-in-human phase I study
Presenter: Li Zhang
Session: Mini oral session 1 - NSCLC, metastatic
Resources:
Abstract
Slides
Webcast
1303P - Immune-modulating effects on tumor draining lymph nodes following neoadjuvant chemoradiotherapy combined with immunotherapy in patients with T3-4N0-1 NSCLC
Presenter: Ezgi Ulas
Session: Poster session 04
Invited Discussant 1314MO, 1315MO and 1316MO
Presenter: Jordi Remon Masip
Session: Mini oral session 1 - NSCLC, metastatic
Resources:
Slides
Webcast
Duration of IO treatment
Presenter: Benjamin Besse
Session: Open questions in immunotherapy for advanced NSCLC: Duration of IO, combinations and rechallenge
Resources:
Slides
Webcast
Neo adjuvant only
Presenter: Rafal Dziadziuszko
Session: Adjuvant or neoadjuvant immunotherapy or both in localised NSCLC
Resources:
Slides
Webcast
Presentation of case/condition
Presenter: Johan Vansteenkiste
Session: Managing stage III NSCLC in the era of IO
Resources:
Slides
Webcast